Item | Information |
---|---|
CAS RN | 80214-83-1 |
Chemical Name | Roxithromycin |
Substance ID | m-nite-80214-83-1_v1 |
Download of Excel format | Excel file |
Item | Information |
---|---|
Guidance used for the classification (External link) | To Guidance List |
UN GHS document (External link) | To UN GHS document |
FAQ(GHS classification results by the Japanese Government) | To FAQ |
List of Information Sources (Excel file) | List of Information Sources |
List of Definitions/Abbreviations | Definitions/Abbreviations |
Sample Label by MHLW (External link) | MHLW Website (in Japanese Only) |
Sample SDS by MHLW (External link) | MHLW Website (in Japanese Only) |
OECD/eChemPortal (External link) | To OECD/eChemPortal (External link) |
Hazard class | Classification | Pictogram Signal word |
Hazard statement (code) |
Precautionary statement (code) |
Rationale for the classification | Classification year (FY) | GHS Classification Guidance for the Japanese Government | |
---|---|---|---|---|---|---|---|---|
1 | Explosives | Not classified (Not applicable) |
- |
- | - | There are no chemical groups associated with explosive properties present in the molecule. It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
2 | Flammable gases | Not classified (Not applicable) |
- |
- | - | Solid (GHS definition). It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
3 | Aerosols | Not classified (Not applicable) |
- |
- | - | Not aerosol products. It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
4 | Oxidizing gases | Not classified (Not applicable) |
- |
- | - | Solid (GHS definition). It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
5 | Gases under pressure | Not classified (Not applicable) |
- |
- | - | Solid (GHS definition). It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
6 | Flammable liquids | Not classified (Not applicable) |
- |
- | - | Solid (GHS definition). It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
7 | Flammable solids | Classification not possible |
- |
- | - | No data available. | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
8 | Self-reactive substances and mixtures | Not classified (Not applicable) |
- |
- | - | There are no chemical groups associated with explosive or self-reactive properties present in the molecule. It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
9 | Pyrophoric liquids | Not classified (Not applicable) |
- |
- | - | Solid (GHS definition). It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
10 | Pyrophoric solids | Not classified |
- |
- | - | It was classified as "Not classified" because it is estimated that it does not ignite at normal temperatures from information that it is stable to temperatures, humidity, and light (Pharmaceutical Interview Forms (Roxithromycin 150 mg tablets (Revised 2018))). | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
11 | Self-heating substances and mixtures | Not classified |
- |
- | - | It was classified as "Not classified" because it is estimated that it does not ignite at normal temperatures from information that it is stable to temperatures, humidity, and light (Pharmaceutical Interview Forms (Roxithromycin 150 mg tablets (Revised 2018))). | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
12 | Substances and mixtures which, in contact with water, emit flammable gases | Not classified (Not applicable) |
- |
- | - | The chemical structure of the substance does not contain metals or metalloids (B, Si, P, Ge, As, Se, Sn, Sb, Te, Bi, Po, At). It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
13 | Oxidizing liquids | Not classified (Not applicable) |
- |
- | - | Solid (GHS definition). It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
14 | Oxidizing solids | Classification not possible |
- |
- | - | The substance is an organic compound containing oxygen (but not fluorine or chlorine) which is chemically bonded to the element other than carbon or hydrogen (N). However, the classification is not possible due to no data. | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
15 | Organic peroxides | Not classified (Not applicable) |
- |
- | - | Organic compounds containing no bivalent -O-O- structure in the molecule. It was classified as "Not classified (Not applicable)." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
16 | Corrosive to metals | Classification not possible |
- |
- | - | Classification is not possible because test methods applicable to solid substances are not available. | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
17 | Desensitized explosives | Not classified |
- |
- | - | There are no chemical groups associated with explosive properties present in the molecule. It was classified as "Not classified." | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
Hazard class | Classification | Pictogram Signal word |
Hazard statement (code) |
Precautionary statement (code) |
Rationale for the classification | Classification year (FY) | GHS Classification Guidance for the Japanese Government | |
---|---|---|---|---|---|---|---|---|
1 | Acute toxicity (Oral) | Category 4 |
Warning |
H302 | P301+P312 P264 P270 P330 P501 |
[Rationale for the Classification] Based on (1), it was classified in Category 4. [Evidence Data] (1) LD50 for rats: male: 1,059 mg/kg, female: 1,712 mg/kg (Pharmaceutical Interview Forms (Roxithromycin 150 mg tablets (Revised 2018))). |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
1 | Acute toxicity (Dermal) | Classification not possible |
- |
- | - | [Rationale for the Classification] Classification not possible due to lack of data. |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
1 | Acute toxicity (Inhalation: Gases) | Not classified (Not applicable) |
- |
- | - | [Rationale for the Classification] Solid (GHS definition). It was classified as "Not classified (Not applicable)." |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
1 | Acute toxicity (Inhalation: Vapours) | Classification not possible |
- |
- | - | [Rationale for the Classification] Classification not possible due to lack of data. |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
1 | Acute toxicity (Inhalation: Dusts and mists) | Classification not possible |
- |
- | - | [Rationale for the Classification] Classification not possible due to lack of data. |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
2 | Skin corrosion/irritation | Classification not possible |
- |
- | - | [Rationale for the Classification] Classification not possible due to lack of data. |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
3 | Serious eye damage/eye irritation | Classification not possible |
- |
- | - | [Rationale for the Classification] Classification not possible due to lack of data. |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
4 | Respiratory sensitization | Classification not possible |
- |
- | - | [Rationale for the Classification] Classification not possible due to lack of data. |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
4 | Skin sensitization | Classification not possible |
- |
- | - | [Rationale for the Classification] Although there is a description in (1), it was classified as "Classification not possible" due to lack of data. [Reference Data, etc.] (1) No antigenicity was observed in a delayed skin reaction (guinea pigs) (Pharmaceutical Interview Forms (Roxithromycin 150 mg tablets (Revised 2018))). |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
5 | Germ cell mutagenicity | Not classified |
- |
- | - | [Rationale for the Classification] Based on (1) and (2), since the results of all standard combination tests, including in vivo and in vitro tests, were negative, it was classified as "Not classified." [Evidence Data] (1) As for in vivo, there is a report on a negative result in a micronucleus test with mice (Pharmaceutical Interview Forms (Roxithromycin 150 mg tablets (Revised 2018))). (2) As for in vitro, there is a report of negative results in a bacterial reverse mutation test, and a mouse lymphoma test and an unscheduled DNA synthesis test with cultured mammalian cells (Pharmaceutical Interview Forms (Roxithromycin 150 mg tablets (Revised 2018))). |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
6 | Carcinogenicity | Classification not possible |
- |
- | - | [Rationale for the Classification] Classification not possible due to lack of data. |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
7 | Reproductive toxicity | Category 2, |
Warning |
H361 H362 |
P308+P313 P201 P202 P260 P263 P264 P270 P280 P405 P501 |
[Rationale for the Classification] Based on (1) and (2), it was classified in Category 2. In addition, based on (3), "additional category for effects on or via lactation" was added to the classification. [Evidence Data] (1) Based on a report of increased frequencies of fetal external and skeletal abnormalities in rats at doses about 80 times higher than the clinical doses, it is described that "pregnant women or women who may be pregnant should be administered this drug only if the expected therapeutic benefits outweigh the possible risks associated with treatment" (Ethical Pharmaceuticals 2017 (2016)). (2) An increase in the number of fetal deaths, growth retardation, and external and skeletal abnormalities were observed at doses where toxicities such as general condition worsening were manifested in maternal animals in a test with rats dosed orally during organogenesis (Pharmaceutical Interview Forms (Roxithromycin 150 mg tablets (Revised 2018))). (3) There is a description that "Administration to lactating women should be avoided, and breast-feeding should be discontinued when administration to a breast-feeding woman is inevitable" based on a report that transfer of this substance in milk was observed in rats (Ethical Pharmaceuticals 2017 (2016)). |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
8 | Specific target organ toxicity - Single exposure | Category 1 (blood system, gastrointestinal tract, liver) |
Danger |
H370 | P308+P311 P260 P264 P270 P321 P405 P501 |
[Rationale for the Classification] This substance is a macrolide antibiotic and is a drug used in the treatment of various bacterial infections by oral administration. In a single dose clinical test in (1), symptoms of the gastrointestinal tract and blood system were observed, and in (2), although the number of doses is unknown, symptoms of the gastrointestinal tract and liver were observed as side effects, therefore, it was classified in Category 1 (blood system, gastrointestinal tract, liver). As for eosinophilia in (2), it was not adopted as evidence because there is a possibility of changes due to hypersensitivity, etc. [Evidence Data] (1) In a clinical pharmacology/tolerability test, when healthy adult men (total of 24 subjects) were given a single oral dose at 300 mg (potency), diarrhea (1 subject), loose stool (2 subjects) and increased reticulocytes (3 subjects) were observed (Pharmaceutical Interview Forms (Roxithromycin 150 mg tablets (Revised 2018))). (2) Although the number of doses is unknown, the main side effects observed were hematological (eosinophilia), hepatic (increased AST, ALT, ALP, etc.) and gastrointestinal (stomach discomfort, abdominal pain, diarrhea, vomiting, etc.) symptoms at a frequency of 0.1 to < 5% (Ethical Pharmaceuticals 2017 (2016)). [Reference Data, etc.] (3) As for serious side effects (incidences were unknown in every case), QT prolongation, ventricular tachycardia (including Torsades de pointes) or ventricular fibrillation, fulminant hepatitis, hepatic dysfunction, jaundice or hepatic failure, thrombocytopenia, pancytopenia, hemolytic anemia, leukopenia or agranulocytosis, PIE syndrome/interstitial pneumonia, pseudomembranous colitis or hemorrhagic colitis, rhabdomyolysis, convulsion, and acute nephropathy or tubulointerstitial nephritis, etc. were reported (Ethical Pharmaceuticals 2017 (2016)). |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
9 | Specific target organ toxicity - Repeated exposure | Category 1 (gastrointestinal tract, liver) |
Danger |
H372 | P260 P264 P270 P314 P501 |
[Rationale for the Classification] Based on (1), major side effects were observed in the gastrointestinal tract and liver. Therefore, it was classified in Category 1 (gastrointestinal tract, liver). [Evidence Data] (1) In humans, side effects (including abnormal laboratory values) were observed in 202 cases (2.27%) out of 8,903 of total cases. The major side effects were increased ALT in 42 cases (0.47%), increased AST in 32 cases (0.36%), eosinophilia in 24 cases (0.27%), diarrhea in 14 cases (0.16%) and stomach discomfort in 13 cases (0.15%) (Ethical Pharmaceuticals 2017 (2016)). Eosinophilia was not adopted as evidence because of the possibility of changes due to hypersensitivity, etc. [Reference Data, etc.] (2) It is reported that as for serious side effects in humans (incidences were unknown in every case), shock or anaphylaxis, pseudomembranous colitis or hemorrhagic colitis, interstitial pneumonia, thrombocytopenia, hepatic dysfunction or jaundice, oculomucocutaneous syndrome (Stevens-Johnson syndrome), and QT prolongation or ventricular tachycardia (including Torsades de pointes) may appear (Ethical Pharmaceuticals 2017 (2016)). (3) In a 6-month repeated dose toxicity test with dogs by the oral route, decreases in body weight and food consumption, increases in ALT (GPT) and ALP, fibrosis of the liver and bile duct tissues, bile duct hyperplasia, and atrophy of the testes and prostate were observed at 100 mg/kg/day (within the range of Category 2) (Pharmaceutical Interview Forms (Roxithromycin 150 mg tablets (Revised 2018))). |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
10 | Aspiration hazard | Classification not possible |
- |
- | - | [Rationale for the Classification] Classification not possible due to lack of data. |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
Hazard class | Classification | Pictogram Signal word |
Hazard statement (code) |
Precautionary statement (code) |
Rationale for the classification | Classification year (FY) | GHS Classification Guidance for the Japanese Government | |
---|---|---|---|---|---|---|---|---|
11 | Hazardous to the aquatic environment Short term (Acute) | Category 1 |
Warning |
H400 | P273 P391 P501 |
It was classified in Category 1 from 72-hour ErC50 = 0.047 mg/L for algae (Pseudokirchneriella subcapitata) (Environmental Risk Assessment for Chemical Substances Vol. 17 (Ministry of the Environment, 2019)). | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
11 | Hazardous to the aquatic environment Long term (Chronic) | Category 1 |
Warning |
H410 | P273 P391 P501 |
If chronic toxicity data are used, then it is classified in Category 1 due to being not rapidly degradable (BIOWIN), and 72-hour NOEC = 0.01 mg/L for algae (Pseudokirchneriella subcapitata) (Environmental Risk Assessment for Chemical Substances Vol. 17 (Ministry of the Environment, 2019)). If acute toxicity data are used for a trophic level for which chronic toxicity data are not obtained, then it is classified in Category 3 due to being not rapidly degradable (BIOWIN), and 48-hour EC50 = 74.3 mg/L for crustacea (Daphnia magna) (Environmental Risk Assessment for Chemical Substances Vol. 17 (Ministry of the Environment, 2019)). By drawing a comparison between the above results, it was classified in Category 1. |
FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
12 | Hazardous to the ozone layer | Classification not possible |
- |
- | - | Classification not possible due to lack of data. | FY2019 | GHS Classification Guidance for the Japanese Government (FY2013 revised edition (Ver. 1.1)) |
|